Horizon scanning: latanoprostene bunod enters into phase III glaucoma study

Source: PharmaTimes Area: News According to a Pharmatimes report, latanoprostene bunod, a novel nitric oxide-donating prostaglandin F2-alpha analogue, will be evaluated in two phase III studies which will include approximately 800 patients with glaucoma or ocular hypertension. The primary endpoint is the reduction in mean intraocular pressure (IOP) measured at specified time points during three months of treatment.   In a phase IIb study in 413 patients, the drug demonstrated that all four doses showed greater IOP reduction compared with latanoprost; the differences for two of the four doses reached statistical significance.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news